IGF-1 LR3 vs ANP (Atrial Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | ANP (Atrial Natriuretic Peptide) |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. |
| Best For |
What They Have in Common
Both IGF-1 LR3 and ANP (Atrial Natriuretic Peptide) are commonly used for: